Echocardiographic evaluation of the effects of gallopamil on left ventricular function

Enrique Z. Fisman*, Amos Pines, Efraim Ben-Ari, Robert J. Shiner, Yaacov Drory, Basil A. Friedman, Jan J. Kellermann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Two-dimensional echocardiography was used to determine global and regional left ventricular function in 32 patients treated with gallopamil (methoxyverapamil) for angina pectoris. Ejection fraction (EF), pressure/volume ratio (PVR), and segmental wall motion were assessed. Evaluations were made before therapy (T1) and repeated 3 weeks later; this assessment included examination 2 and 8 hours after the morning dose (T2, and T3, respectively). Patients were randomized to either a placebo group or three study groups (25, 37.5, and 50 mg t.i.d.). In the 37.5 and 50 mg groups there was an increase in EF (T1 = 53.8% and 54.5%, T2 = 57.9% and 60.1%, and T3 = 57.6% and 60%) and PVR values (T1 = 5.2 and 7.2 mm Hg/ml/m2, T2 = 5.8 and 7.7 mm Hg/ml/m2, and T3 = 5.9 and 7.6 mm Hg/ml/m2, respectively). Wall motion remained the same or improved in 92.3% of the patients. In conclusion, gallopamil had no cardiodepressant effects in most patients. On the contrary, EF, PVR, and segmental contractility tended to improve with the higher doses.

Original languageEnglish
Pages (from-to)100-106
Number of pages7
JournalClinical Pharmacology and Therapeutics
Issue number1
StatePublished - Jul 1988


Dive into the research topics of 'Echocardiographic evaluation of the effects of gallopamil on left ventricular function'. Together they form a unique fingerprint.

Cite this